about
Sulfonylurea receptor 1 in central nervous system injury: a focused reviewPharmacotherapy of end-stage renal disease.Risks of combined alcohol/medication use in older adults.Characterization of the binding of sulfonylurea drugs to HSA by high-performance affinity chromatography.Effects of current therapeutic interventions on insulin resistance.Chromatographic analysis of acetohexamide binding to glycated human serum albuminBinding of tolbutamide to glycated human serum albuminUse of peak decay analysis and affinity microcolumns containing silica monoliths for rapid determination of drug-protein dissociation rates.Analysis of free drug fractions by ultrafast affinity extraction: interactions of sulfonylurea drugs with normal or glycated human serum albumin.High-performance affinity chromatography and the analysis of drug interactions with modified proteins: binding of gliclazide with glycated human serum albuminEffect of sulfonylureas administered centrally on the blood glucose level in immobilization stress modelPrevention and treatment of the metabolic syndrome.Studies of drug interactions with glycated human serum albumin by high-performance affinity chromatography.Analysis of drug interactions with modified proteins by high-performance affinity chromatography: binding of glibenclamide to normal and glycated human serum albuminDevelopment of affinity microcolumns for drug-protein binding studies in personalized medicine: interactions of sulfonylurea drugs with in vivo glycated human serum albuminExfoliation, cholestasis, and apparent biliary sepsis in a woman with adult-onset diabetes.Antidiabetic Therapy in End-Stage Renal Disease.Liquigroud technique: a new concept for enhancing dissolution rate of glibenclamide by combination of liquisolid and co-grinding technologies.Non-insulin-dependent diabetes mellitus. Current status of oral hypoglycemic therapy.Drug interactions, renal impairment and hypoglycaemia in a patient with Type II diabetes.Management of hyperglycemia in patients with diabetes mellitus and chronic renal failure.Identification of oral antidiabetics and their metabolites in human urine by liquid chromatography/tandem mass spectrometry--a matter for doping control analysis.Glibenclamide prevents increased extracellular matrix formation induced by high glucose concentration in mesangial cells.Unaltered drug metabolizing enzyme systems in type II diabetes mellitus before and during glyburide therapy.An evaluation of the therapeutic effects and dosage equivalence of glyburide and glipizide.
P2860
Q24606564-1CCF3856-E113-48D6-AC76-FCB61E67B5D2Q33531889-52E59E30-650B-4C70-99D1-8C48DC2F8A25Q33776601-88E2D873-FB00-441B-930D-75C28FA80AF8Q33876316-DC5EF513-6511-4A7A-B1BC-7C68512E91CDQ34163110-FC1D7FC1-671A-4D04-B033-C76C002CE3B9Q34189372-669B3FD0-9C0F-4C5F-A89E-6DC517B13EBEQ34233297-36FD3A8E-62FE-435C-A7C5-66B2C87A9CF8Q34507719-1BA49660-EF31-4379-B133-291CAEE67BC2Q34625180-22889493-2622-451F-A793-39C0752EBBD1Q35490770-D1BF779E-36A6-4B8A-AF9D-FB7FD3C27DB0Q35578586-D4C29D2E-2C80-4612-A5E0-7D03243A7EC3Q35952447-CD201D22-2968-4406-88AC-BDB8B3376787Q36216660-8ABCCB3B-DF25-471E-B07F-24E5D0C5BE58Q36371289-74636CC4-2572-49EE-84D5-5A8E101C1586Q36966255-50A32284-6F3E-4575-A371-97D4AF235235Q36988972-2DE8D9C5-0D27-419B-BCD9-ACEBD190C48CQ38433245-0754F767-BD97-40F0-B796-701C426D38C5Q38762614-5A02D1C1-4DBE-4F45-A936-FBF1E76FCDE6Q41327011-0357A2EC-4F20-4E41-BF54-3526A353277CQ41594683-2DF1B0FA-A0F7-409E-972F-75DAD31D538DQ42157131-E9CD1349-7FBC-4D3C-9DD6-1E318225B0FEQ45300992-E26E4160-B340-49D5-97D9-FD396B78B9ECQ51149604-34E6391F-CDA4-4859-85B2-DC8F442AD8E1Q51614203-DD687935-1BEE-412C-B843-CA794F87FFDEQ51617077-487D61B2-032F-4E8A-9794-2516E4BC8FB7
P2860
description
1981 nî lūn-bûn
@nan
1981 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1981 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1981年の論文
@ja
1981年論文
@yue
1981年論文
@zh-hant
1981年論文
@zh-hk
1981年論文
@zh-mo
1981年論文
@zh-tw
1981年论文
@wuu
name
The pharmacology of sulfonylureas.
@ast
The pharmacology of sulfonylureas.
@en
The pharmacology of sulfonylureas.
@nl
type
label
The pharmacology of sulfonylureas.
@ast
The pharmacology of sulfonylureas.
@en
The pharmacology of sulfonylureas.
@nl
prefLabel
The pharmacology of sulfonylureas.
@ast
The pharmacology of sulfonylureas.
@en
The pharmacology of sulfonylureas.
@nl
P1476
The pharmacology of sulfonylureas.
@en
P2093
Feldman JM
Skillman TG
P304
P356
10.1016/0002-9343(81)90773-7
P407
P577
1981-02-01T00:00:00Z